patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
baricitinib - versus control - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 0.68 [0.51, 0.91]< 1 65% 4 studies (4/-) 99.6 % low not evaluable high crucial - death or transfer to ICU 0.93 [0.87, 0.99]< 1 0% 1 study (-/1) 98.6 % NA not evaluable crucial - deaths 0.62 [0.46, 0.84]< 1 67% 6 studies (4/2) 99.9 % low serious high crucial - deaths (time to event analysis only) 0.59 [0.45, 0.78]< 1 0% 2 studies (2/-) 100.0 % low not evaluable high crucial - clinical deterioration 1.12 [0.58, 2.16]< 1 0% 1 study (1/-) 36.8 % NA not evaluable important - clinical improvement 1.24 [1.03, 1.48]> 1 46% 3 studies (3/-) 99.0 % low not evaluable high important - clinical improvement (14-day) 1.31 [1.13, 1.52]> 1 0% 3 studies (3/-) 100.0 % low not evaluable high important - clinical improvement (28-day) 1.82 [0.87, 3.81]> 1 0% 1 study (1/-) 94.4 % NA not evaluable important - clinical improvement (time to event analysis only) 1.16 [1.01, 1.33]> 1 0% 1 study (1/-) 98.5 % NA not evaluable important - death or ventilation 0.82 [0.65, 1.05]< 1 58% 2 studies (2/-) 93.9 % some concern not evaluable moderate important - hospital discharge 23.94 [10.77, 53.20]> 1 0% 1 study (-/1) 100.0 % NA not evaluable important - mechanical ventilation 0.78 [0.59, 1.04]< 1 55% 2 studies (2/-) 95.3 % some concern not evaluable moderate important - ICU admission 0.12 [0.03, 0.49]< 1 49% 2 studies (-/2) 99.8 % low not evaluable high non important - recovery 1.57 [0.77, 3.20]> 1 0% 1 study (1/-) 89.3 % NA not evaluable non important - safety endpoints 00 superinfection 0.50 [0.32, 0.79]< 1 0% 1 study (1/-) 99.8 % NA not evaluable important - acute kidney injury 0.43 [0.14, 1.34]< 1 0% 1 study (-/1) 92.7 % NA not evaluable non important - arrhythmia 0.16 [0.03, 0.90]< 1 0% 1 study (-/1) 98.1 % NA not evaluable non important - elevated liver enzymes 0.52 [0.18, 1.51]< 1 0% 1 study (-/1) 88.5 % NA not evaluable non important - Myocardial infarction 0.87 [0.19, 3.92]< 1 0% 1 study (-/1) 57.2 % NA not evaluable non important - venous thromboembolism 5.23 [0.42, 65.62]< 1 0% 1 study (-/1) 10.2 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.